Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cipla
Boehringer Ingelheim
Fish and Richardson
Mallinckrodt
Chubb
Moodys
Dow
Daiichi Sankyo
Deloitte
Cerilliant

Generated: February 19, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022573

« Back to Dashboard

NDA 022573 describes NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, which is a drug marketed by Accord Hlthcare, Amneal Pharms, Apil, Barr, Lupin Ltd, and Mylan Labs Ltd, and is included in seven NDAs. It is available from five suppliers. There is one patent protecting this drug. Additional details are available on the NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE profile page.

The generic ingredient in NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE is ethinyl estradiol; norethindrone. There are twenty-six drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; norethindrone profile page.
Summary for 022573
Tradename:NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE
Applicant:Apil
Ingredient:ethinyl estradiol; norethindrone
Patents:1
Formulation / Manufacturing:see details
Suppliers and Packaging for NDA: 022573
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE ethinyl estradiol; norethindrone TABLET, CHEWABLE;ORAL 022573 NDA Allergan, Inc. 0023-6030 N 0023-6030-03
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE ethinyl estradiol; norethindrone TABLET, CHEWABLE;ORAL 022573 NDA Actavis Pharma, Inc. 52544-064 N 52544-064-31

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, CHEWABLE;ORALStrength0.025MG;0.8MG
Approval Date:Dec 22, 2010TE:ABRLD:Yes
Patent:➤ Sign UpPatent Expiration:Apr 6, 2019Product Flag?YSubstance Flag?Delist Request?
Patented Use:PREVENTION OF PREGNANCY IN WOMEN WHO ELECT TO USE ORAL CONTRACEPTIVES AS A METHOD OF CONTRACEPTION

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Chubb
Farmers Insurance
Julphar
QuintilesIMS
Dow
Express Scripts
Boehringer Ingelheim
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot